AwesomeCapital

AstraZeneca (NASDAQ:AZN) Q3 results:
Revenues: $6,578M (+3%); Product Sales: $6,520M (+6%); Collaboration Revenue: $258M (-79%).
Key product sales: Tagrisso: $1,155M (+30%); Imfinzi: $533M (+29%); Lynparza: $464M (+42%); Symbicort: $599M (-2%); Farxiga: $527M (+32%); Brilinta: $385M (-7%); Nexium: $409M (+7%); Crestor: $301M (-13%); Zoladex: $233M (+1%); Fasenra: $240M (+19%).
Diversified growth continued across therapy areas and geographically. However, China Pulmicort COVID-19 impact reduced the development.
Net Income: $651M (+132.5%); EPS: $0.49 (+113%); non-GAAP EPS: $0.94 (-4%).
CF Ops: $3,001M (+88.3%)
2020 Guidance (at CER): Total revenue: growth increase by a high-single digit to a low-double digit percentage (unch); Core EPS: to increase by a mid- to high teens percentage (unch).
https://seekingalpha.com/news/3631829-astrazeneca-q3-lynparza-salesplus-42-farxiga-sales-up-32-guidance-reiterated

CIGNA (NYSE:CI): Q3 Non-GAAP EPS of $4.41 beats by $0.18; GAAP EPS of $3.78 beats by $0.61.
Revenue of $40.8B (+13.9% Y/Y) beats by $1.61B.
Press Release
https://seekingalpha.com/news/3631880-cigna-eps-beats-0_18-beats-on-revenue

Becton, Dickinson (NYSE:BDX) fiscal Q4 results:
Revenues: $4,784M (+4.4%); BD Medical: $2,318M (-4.9%); BD Life Sciences: $1,488MM (+31.2%); BD Interventional: $978M (-3.4%).
BD Life Sciences sales were driven by strong sales related to COVID-19 diagnostic testing solutions in the Diagnostic Systems unit on the BD Veritor and BD Max platforms.
Net Income: $105M (-15.9%); EPS: $0.36 (-20.0%); non-GAAP EPS: $2.79 (-15.7%).
CF Ops: $3,539M (+6.3%).
FY 2021 Guidance: Revenue growth: high single to low double-digits; non-GAAP EPS: non-GAAP EPS: $12.40 - 12.60 (consensus: $12.53).
https://seekingalpha.com/news/3631911-becton-dickinson-beats-fq4-consensus-life-sciences-revenueplus-31-driven-strong-covidminus-19

Regeneron Pharmaceuticals (NASDAQ:REGN) Q3 results:
Revenues: $2,294M (+32%); Eylea total sales: $2,098.3M (+9%); Dupixent global net sales: $1,072.6M (+69%); Libtayo global sales: $96.1M (+87%); Praluent: $91.5M (+31%); Kevzara: $70M (+28%); REGN-COV2: $40.2M.
Net Income: $842M (+26%); EPS: $7.39 (+26%); non-GAAP Net Income: $961M (+26%); non-GAAP EPS: $8.36 (+25%).
Net cash used in operations (3 months): $254.3M.
The Company had robust top and bottom line growth driven by EYLEA in retinal diseases and Dupixent in atopic dermatitis and asthma.
In 2021, REGN looks forward to potential launches including PD-1 inhibitor Libtayo in non-small cell lung cancer and advanced basal cell carcinoma.
Lastly, Regeneron's novel antibody cocktail REGN-EB3 recently became the first FDA-approved treatment for Ebola.

https://seekingalpha.com/news/3631946-regeneron-pharma-posts-strong-q3-driven-robust-dupixent-and-libtayo-sales

Merck (NYSE:MRK) strengthens its oncology pipeline, as it has agreed to acquire privately-held VelosBio for $2.75B.
VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate targeting ROR1, and is currently being evaluated in a Phase 1 and a Phase 2 trial for the treatment of patients with hematologic malignancies and solid tumors, respectively.
The deal is expected to close by end of this year.
https://seekingalpha.com/news/3631943-merck-scoops-up-velosbio-for-2_75b

Cardinal Health (NYSE:CAH): FQ1 Non-GAAP EPS of $1.51 beats by $0.37; GAAP EPS of -$0.86 misses by $1.66.
Revenue of $39.07B (+4.6% Y/Y) beats by $930M.
The company raised FY2021 adjusted EPS outlook to $5.65-$5.95 vs. prior outlook of $5.25-$5.65 and consensus of $5.48.
Shares +3.16% PM.
Press Release
https://seekingalpha.com/news/3631951-cardinal-health-eps-beats-0_37-beats-on-revenue

ANI Pharmaceuticals (NASDAQ:ANIP): Q3 Non-GAAP EPS of $0.97 beats by $0.09; GAAP EPS of $0.04 beats by $0.14.
Revenue of $52.98M (+3.2% Y/Y) beats by $1.48M.
Press Release
https://seekingalpha.com/news/3631958-ani-pharmaceuticals-eps-beats-0_09-beats-on-revenue

Search This Blog